reports
Boryung: 1 director
A director at Boryung bought 5,000 shares at 7,970.000KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Yang Ku Kang
Boryung Pharm (003850.KS): Bottom confirmed
- We keep our BUY rating intact for the mid/long term as Boryung Pharm’s key original medicine “Kanarb” and its family at home and abroad gains growth momentum. - However, we cut our target price to KRW50,000 from KRW62,000 as outpatient prescriptions have been falling over the past two months and the recognition of KRW73bn in proceeds from the disposal of a property is likely to be delayed to 1H18 from 2H17.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.